ArticleInternational journal of molecular sciences2019
Multiple Glycation Sites in Blood Plasma Proteins as an Integrated Biomarker of Type 2 Diabetes Mellitus.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Next-generation diabetes diagnostics: spectrochemical staging of red blood cells using vibrational spectroscopy.Journal of advanced research · 2026Article
- Screening of binding by antidiabetic drugs to normal vs AGE-modified human serum albumin through covalent immobilization and microscale affinity chromatography.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026Article
- A history of maternal separation drives systemic aging-associated signatures in middle-aged male rats.Frontiers in cellular neuroscience · 2026Article
- Advances in Targeting the AGEs-RAGE Pathway for the Treatment of Diabetic Kidney Disease.Drug design, development and therapy · 2026Review
- Advanced glycated end-products modified transferrin mediates oxidative stress and ferroptosis in podocytes via advanced glycation end-product receptor in vitro.Scientific reports · 2025Article
- Affinity on Demand: A One-Pot Method for Synthesis and Sample Enrichment Using TentaGel-Functionalized Resins.ACS omega · 2025Article
- Proteome and Metabolome Alterations in Radish (Biomolecules · 2025Article
- A proposed model using glycation metrics and circulating biomarkers for the prevention of cardiovascular disease.Frontiers in medicine · 2025Article
- Pregestational Prediabetes Induces Maternal Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation and Results in Adverse Foetal Outcomes.International journal of molecular sciences · 2024Article
- Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review.Metabolites · 2024Review
- Glyoxal in hyperglycaemic ischemic stroke - a cohort study.Cardiovascular diabetology · 2023Article
- Elevated Level of Glycated KQTALVELVK Peptide of Albumin Is Associated with the Risk of Diabetic Nephropathy.ACS omega · 2023Article
- Detergent-Assisted Protein Digestion-On the Way to Avoid the Key Bottleneck of Shotgun Bottom-Up Proteomics.International journal of molecular sciences · 2022Review
- Optical Measurement of Molar Absorption Coefficient of HbA1c: Comparison of Theoretical and Experimental Results.Sensors (Basel, Switzerland) · 2022Article
- Analytical Challenges in Diabetes Management: Towards Glycated Albumin Point-of-Care Detection.Biosensors · 2022Review
- Effect of transferrin glycation induced by high glucose on HK-2 cellsFrontiers in endocrinology · 2022Article
- Effects of Subcortical Atrophy and Alzheimer's Pathology on Cognition in Elderly Type 2 Diabetes: The Alzheimer's Disease Neuroimaging Initiative Study.Frontiers in aging neuroscience · 2022Article
- Serum Albumin in Health and Disease: Esterase, Antioxidant, Transporting and Signaling Properties.International journal of molecular sciences · 2021Review
- Integrative Role of Albumin: Evolutionary, Biochemical and Pathophysiological Aspects.Journal of evolutionary biochemistry and physiology · 2021Article
- Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) is one of the most widely spread metabolic diseases. Because of its asymptomatic onset and slow development, early diagnosis and adequate glycaemic control are the prerequisites for successful T2DM therapy. In this context, individual amino acid residues might be sensitive indicators of alterations in blood glycation levels. Moreover, due to a large variation in the half-life times of plasma proteins, a generalized biomarker, based on multiple glycation sites, might provide comprehensive control of the glycemic status across any desired time span. Therefore, here, we address the patterns of glycation sites in highly-abundant blood plasma proteins of T2DM patients and corresponding age- and gender-matched controls by comprehensive liquid chromatography-mass spectrometry (LC-MS). The analysis revealed 42 lysyl residues, significantly upregulated under hyperglycemic conditions. Thereby, for 32 glycation sites, biomarker behavior was demonstrated here for the first time. The differentially glycated lysines represented nine plasma proteins with half-lives from 2 to 21 days, giving access to an integrated biomarker based on multiple protein-specific Amadori peptides. The validation of this biomarker relied on linear discriminant analysis (LDA) with random sub-sampling of the training set and leave-one-out cross-validation (LOOCV), which resulted in an accuracy, specificity, and sensitivity of 92%, 100%, and 85%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.